Change in clinical outcome measures with recombinant chaperonin 10, at a dose of 10 mg twice weekly for 12 weeks. A, Change in Psoriasis Area Severity Index (PASI) score. B, Change in Physician Global Assessment (PGA) score. C, Percentage of patients achieving a 50% or greater improvement in PASI score (PASI 50) or a 75% or greater improvement in PASI score (PASI 75). D, Change in cytokine production by patient-derived peripheral blood mononuclear cells. The error bars in A, B, and D show 95% confidence intervals. *.01<P > .046 (Wilcoxon-signed rank test). TNF-α indicates tumor necrosis factor α; IL-1β, interleukin 1β. Screen refers to a baseline measurement; it was performed 7 ± 2 days prior to the first dose (day 0). Follow-up assessment was performed on day 112 of the trial, 4 weeks after dosing had stopped.
Williams B, Vanags D, Hall S, McCormack C, Foley P, Weiss J, Johnson B, Latz E, Feeney D. Efficacy and Safety of Chaperonin 10 in Patients With Moderate to Severe Plaque Psoriasis: Evidence of Utility Beyond a Single Indication. Arch Dermatol. 2008;144(5):683-685. doi:10.1001/archderm.144.5.683
Chaperonin 10 is a highly conserved protein that is essential in protein folding. Recombinant chaperonin 10 (Cpn10) (1 amino acid different to native chaperonin 10) and has immunomodulatory function in vitro and in vivo.1,2 Treatment with Cpn10 improved clinical disease activity in patients with rheumatoid arthritis and downregulated cytokine responses of immune cells to cellular stimuli.2 An exploratory study of Cpn10 treatment for chronic plaque psoriasis is reported.
Forty patients were screened, and 24 (aged 18 to 75 years) with plaque psoriasis for at least 6 months prior to screening, 10% or greater of the body surface area affected by plaque psoriasis, a Psoriasis Area and Severity Index (PASI) score of 12 or higher (severe psoriasis), and a Physician's Global Assessment (PGA) score of at least moderate at screening despite current therapies were selected. Patients taking psoriasis medications were eligible if the regimen they had been following was a stable systemic dose for 28 days or longer prior to treatment with Cpn10 or 14 days or longer with topical dosing. Exclusion criteria were infections, malignant neoplasms, abnormal hematology, renal, or liver function test findings, and treatment with any anti–tumor necrosis factor α (TNF-α) agents or immunosuppressive drugs within 28 days of starting Cpn10 treatment. In this single-center, double-blind study, patients were randomized into 5-, 7.5-, and 10-mg treatment groups of Cpn10 (XToll; CBio Limited, Brisbane, Australia) that was given intravenously twice weekly for 12 weeks. Outcomes were PASI and PGA scores and the percentages of patients with at least a 50%, 75%, or 90% improvement in PASI scores (PASI 50, PASI 75, and PASI 90). In vitro peripheral blood mononuclear cell reactivity to lipopolysaccharide stimulation was measured by cytokine production. Safety was assessed by physical examination, adverse event profile, laboratory parameters, and vital signs.
Patients with severe plaque psoriasis showed improvement in disease activity in all dose groups. Median percent change in PASI scores (baseline median, 23.9) decreased by day 14 (P=.01) and further by day 84 (P=.02) in the 10-mg group (Figure, A). Improvement was maintained 4 weeks (P=.03) after cessation of Cpn10 treatment. The PGA (baseline median, 4) showed improvement by day 56 (P=.02) with 10 mg (Figure, B) and continued to improve to days 84 (P=.03) and 112 (P=.03). An almost clear PGA rating was achieved in 3 patients in the 10-mg group. All groups demonstrated a PASI 50 and PASI 75 (Table; Figure, C). A PASI 90 was observed in one patient in the 7.5-mg group on days 56 and 70 and in another patient in the 10-mg group on day 70. No difference was seen in between the dose groups at day 84 in the percentage of patients exhibiting a PASI 75 response (P = .08). Peripheral blood mononuclear cells isolated from patients after treatment with Cpn10 produced significantly less TNF-α (day 28, P=.046; day 56, P = .04) (baseline median, 1397 pg/mL) and interleukin 1β (day 28, P=.046; day 56, P=.03) (baseline median, 2567 pg/mL) in the 10-mg group (Figure, D). The most common adverse event was exacerbation of psoriasis (4 cases during the study and 3 cases after the final dose). Decreased lymphocyte counts were observed in 6 patients, 2 of whom had upper respiratory tract infections. One patient was lymphopenic at screening, possibly associated with concomitant sarcoidosis. One patient with diabetes mellitus experienced loss of consciousness judged to be unrelated to the study drug. Three adverse events were rated as probably treatment related (scotoma, psoriasis flare, increased proteinuria). Four patients showed a 4-fold increase in antibody titer to Cpn10. The relevance for efficacy is unknown as clinical improvement in these patients was seen.
This exploratory study shows preliminary evidence of short-term efficacy and safety and decreased release of TNF-α and interleukin 1β, which is noteworthy in inflammation.3 Lack of placebo is an acknowledged limitation of this pilot study as marked placebo effects are observed in psoriasis studies.4 Nevertheless, short-term Cpn10 treatment led to rapid reduction in disease parameters in accord with our earlier observations of disease-modifying activity in chronic inflammatory processes.1,2 These results will guide the design of a definitive placebo-controlled study and they raise the possibility that Cpn10 may regulate inflammation in a range of therapeutic areas.
Correspondence: Dr Feeney, CBio Limited, 85 Brandl St, Eight Mile Plains, QLD 4113, Australia (email@example.com).
Author Contributions: Dr Feeney had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Study concept and design: Vanags, Hall, McCormack, Foley, Johnson, Latz, and Feeney. Acquisition of data: Vanags, Hall, McCormack, Foley, Johnson, and Latz. Analysis and interpretation of data: Williams, Vanags, Hall, McCormack, Foley, Weiss, Johnson, Latz, and Feeney. Drafting of the manuscript: Williams, Vanags, Hall, McCormack, Foley, Johnson, and Feeney. Critical revision of the manuscript for important intellectual content: Williams, Vanags, Hall, McCormack, Foley, Johnson, Latz, and Feeney. Obtained funding: Feeney. Administrative, technical, or material support: Williams, Vanags, Foley, Weiss, Johnson, Latz, and Feeney. Study supervision: Williams, Vanags, Hall, Foley, and Feeney.
Funding/Support: This study was fully sponsored by CBio Limited. The study was supported in part by a Pharmaceutical Partnerships Program (P3) Grant from the Australian Federal Government.
Role of the Sponsors: CBio Limited participated in the design of the study, oversaw the implementation of the study, organized the analysis of the data, participated in the preparation of the manuscript, and reviewed the manuscript. Dr Feeney approved the manuscript for submission.
Financial Disclosures: Dr Foley has been paid as an investigator for psoriasis trials sponsored by Biogen Idec, Serono, Wyeth, GlaxoSmithKline, and Aventis. He has received honoraria and travel funds from Biogen Idec, Serono, Wyeth, and Schering-Plough for presentations at national and international congresses and scientific meetings. He has received honoraria for attending meetings as a member of Biogen Idec, Serono, Wyeth, and Schering-Plough's medical advisory boards. Dr McCormack has been paid as an investigator for psoriasis trials sponsored by Biogen and Serono. He has received honoraria and travel funds from CSL and Wyeth for presentations at scientific meetings. He has received honoraria for attending a CSL medical advisory board meeting. Dr Hall has been paid as an investigator for clinical trials in psoriasis sponsored by Serono. He has also been paid as an investigator for clinical trials in other medical conditions sponsored by Wyeth, Schering-Plough, Centocor, Amgen, GlaxoSmithKline, Sanofi Aventis, Sanofi Pasteur, MSD, Pfizer, Boehringer Ingelheim, and AstraZeneca. He has received honoraria for presentations from Boehringer Ingelheim, GlaxoSmithKline, Pfizer, MSD, Wyeth, Roche, Sanofi Aventis, and Schering-Plough. He has received honoraria for attending meetings as a member of medical advisory boards of Boehringer Ingelheim, MSD, Servier, Schering Plough, Wyeth, and Roche. Dr Latz received honoraria or was compensated for consultancy by MedImmune/Astra Zeneca, Eisai Pharmaceuticals, and Altana Pharmaceuticals. Mss Williams and Weiss and Drs Vanags, Johnson, and Feeney are employees of CBio Limited and have received stock options from CBio Limited. Dr Latz is an employee of the University of Massachusetts Medical School. Dr Latz is a consultant to CBio Limited and has received stock options from CBio Limited. Drs Hall, McCormack, and Foley were paid by the sponsor to implement the study. There are no further disclosures from any author regarding expert testimony, grants patents, patent applications, or royalties.
Additional Contributions: John Funder, MD, reviewed the manuscript (Professor Funder is a scientific adviser to CBio Limited and has received stock options from CBio Limted); Nathan Tully, BSc(Hons), Lynda Borg, BSc(Hons), Flor de Maria Leon Flores, MSc, and Narelle Hillyard, Cert Biol Lab Tech, assisted with in vitro assays on patient samples; and Christopher Frampton, PhD, Christchurch School of Medicine, University of Otago, provided statistical analysis.